Immune escape by Epstein-Barr virus associated malignancies

Seminars in Cancer Biology

Volumn 18, Issue 6, 2008, Pages 381-387

  Münz, Christian ^a   Moormann, Ann ^b  

^a INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Burkitt's lymphoma; HIV; Hodgkin's lymphoma; Malaria; Nasopharyngeal carcinoma; T cells

Indexed keywords

EPSTEIN BARR VIRUS VACCINE; RECOMBINANT GP350; UNCLASSIFIED DRUG;

BURKITT LYMPHOMA; CANCER IMMUNIZATION; CLINICAL TRIAL; DRUG EFFICACY; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; IMMUNOCOMPETENCE; INFECTIOUS MONONUCLEOSIS; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; NASOPHARYNX CARCINOMA; REVIEW; TUMOR IMMUNITY;

ANTIGENS, VIRAL; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HUMANS; MALARIA, FALCIPARUM; NEOPLASMS; TUMOR ESCAPE; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 56949101640     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2008.10.002     Document Type: Review

References (95)

1. Young L.S., and Rickinson A.B. Epstein-Barr virus: 40 years on. Nat Rev Cancer 4 10 (2004) 757-768
2. Pfeffer S., Zavolan M., Grasser F.A., Chien M., Russo J.J., Ju J., et al. Identification of virus-encoded microRNAs. Science 304 5671 (2004) 734-736
3. Nanbo A., Inoue K., Adachi-Takasawa K., and Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J 21 5 (2002) 954-965
4. Thorley-Lawson D.A., and Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med 350 13 (2004) 1328-1337
5. Babcock J.G., Hochberg D., and Thorley-Lawson A.D. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13 4 (2000) 497-506
6. Hochberg D., Middeldorp J.M., Catalina M., Sullivan J.L., Luzuriaga K., and Thorley-Lawson D.A. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 101 1 (2004) 239-244
7. Babcock G.J., Decker L.L., Volk M., and Thorley-Lawson D.A. EBV persistence in memory B cells in vivo. Immunity 9 3 (1998) 395-404
8. Yin Y., Manoury B., and Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science 301 5638 (2003) 1371-1374
9. Levitskaya J., Coram M., Levitsky V., Imreh S., Steigerwald-Mullen P.M., Klein G., et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375 6533 (1995) 685-688
10. Levitskaya J., Sharipo A., Leonchiks A., Ciechanover A., and Masucci M.G. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 94 23 (1997) 12616-12621
11. Crotzer V.L., Christian R.E., Brooks J.M., Shabanowitz J., Settlage R.E., Marto J.A., et al. Immunodominance among EBV-derived epitopes restricted by HLA-B27 does not correlate with epitope abundance in EBV-transformed B-lymphoblastoid cell lines. J Immunol 164 12 (2000) 6120-6129
12. Boshoff C., and Weiss R. AIDS-related malignancies. Nat Rev Immunol 2 (2002) 373-382
13. Levine A.M. Acquired immunodeficiency syndrome-related lymphoma. Blood 80 1 (1992) 8-20
14. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3 10 (2003) 801-812
15. Kelly G.L., Milner A.E., Baldwin G.S., Bell A.I., and Rickinson A.B. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci USA 103 40 (2006) 14935-14940
16. Hammerschmidt W., and Sugden B. Epstein-Barr virus sustains Burkitt's lymphomas and Hodgkin's disease. Trends Mol Med 10 7 (2004) 331-336
17. Bubman D., Guasparri I., and Cesarman E. Deregulation of c-Myc in primary effusion lymphoma by Kaposi's sarcoma herpesvirus latency-associated nuclear antigen. Oncogene 26 34 (2007) 4979-4986
18. Kelly G.L., and Rickinson A.B. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007 (2007) 277-284
19. Rappold G.A., Hameister H., Cremer T., Adolph S., Henglein B., Freese U.K., et al. c-myc and immunoglobulin kappa light chain constant genes are on the 8q+ chromosome of three Burkitt lymphoma lines with t(2;8) translocations. EMBO J 3 12 (1984) 2951-2955
20. + T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood 106 9 (2005) 3166-3174
21. + T cell counts. PLoS Med 4 3 (2007) e96
22. Lee S.P., Brooks J.M., Al-Jarrah H., Thomas W.A., Haigh T.A., Taylor G.S., et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med 199 (2004) 1409-1420
23. + T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 191 10 (2000) 1649-1660
24. Paludan C., Schmid D., Landthaler M., Vockerodt M., Kube D., Tuschl T., et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307 5709 (2005) 593-596
25. + Th1 cells kill Burkitt's lymphoma cells. J Immunol 169 (2002) 1593-1603
26. + EBV-specific CTLs. J Immunol 158 8 (1997) 3619-3625
27. Rooney C.M., Rowe M., Wallace L.E., and Rickinson A.B. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature 317 6038 (1985) 629-631
28. Torsteinsdottir S., Masucci M.G., Ehlin-Henriksson B., Brautbar C., Ben Bassat H., Klein G., et al. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity. Proc Natl Acad Sci USA 83 15 (1986) 5620-5624
29. Staege M.S., Lee S.P., Frisan T., Mautner J., Scholz S., Pajic A., et al. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells. Proc Natl Acad Sci USA 99 7 (2002) 4550-4555
30. Gavioli R., Frisan T., Vertuani S., Bornkamm G.W., and Masucci M.G. c-myc overexpression activates alternative pathways for intracellular proteolysis in lymphoma cells. Nat Cell Biol 3 3 (2001) 283-288
31. Burkitt D. A children's cancer dependent on climatic factors. Nature 194 (1962) 232-234
32. Epstein M.A., Henle G., Achong B.G., and Barr Y.M. Morphological and biological studies on a virus in cultured lymphoblasts from Burkitt's lymphoma. J Exp Med 121 (1964) 761-770
33. Rochford R., Cannon M.J., and Moormann A.M. Endemic Burkitt's lymphoma: a polymicrobial disease?. Nat Rev Microbiol 3 2 (2005) 182-187
34. Laichalk L.L., and Thorley-Lawson D.A. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol 79 2 (2005) 1296-1307
35. Rasti N., Falk K.I., Donati D., Gyan B.A., Goka B.Q., Troye-Blomberg M., et al. Circulating Epstein-Barr virus in children living in malaria-endemic areas. Scand J Immunol 61 5 (2005) 461-465
36. Moormann A.M., Chelimo K., Sumba O.P., Lutzke M.L., Ploutz-Snyder R., Newton D., et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 191 8 (2005) 1233-1238
37. Donati D., Espmark E., Kironde F., Mbidde E.K., Kamya M., Lundkvist A., et al. Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J Infect Dis 193 7 (2006) 971-977
38. Henle G., Henle W., Clifford P., Diehl V., Kafuko G.W., Kirya B.G., et al. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst 43 5 (1969) 1147-1157
39. Akpogheneta O.J., Duah N.O., Tetteh K.K., Dunyo S., Lanar D.E., Pinder M., et al. Duration of naturally acquired antibody responses to blood stage Plasmodium falciparum is age dependent and antigen specific. Infect Immun (2008)
40. Dorsett Y., Robbiani D.F., Jankovic M., Reina-San-Martin B., Eisenreich T.R., and Nussenzweig M.C. A role for AID in chromosome translocations between c-myc and the IgH variable region. J Exp Med 204 9 (2007) 2225-2232
41. Pasqualucci L., Bhagat G., Jankovic M., Compagno M., Smith P., Muramatsu M., et al. AID is required for germinal center-derived lymphomagenesis. Nat Genet 40 1 (2008) 108-112
42. Ramiro A.R., Jankovic M., Eisenreich T., Difilippantonio S., Chen-Kiang S., Muramatsu M., et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell 118 4 (2004) 431-438
43. He B., Raab-Traub N., Casali P., and Cerutti A. EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol 171 10 (2003) 5215-5224
44. Chene A., Donati D., Guerreiro-Cacais A.O., Levitsky V., Chen Q., Falk K.I., et al. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 3 6 (2007) e80
45. Parroche P., Lauw F.N., Goutagny N., Latz E., Monks B.G., Visintin A., et al. Malaria hemozoin is immunologically inert but radically enhances innate responses by presenting malaria DNA to Toll-like receptor 9. Proc Natl Acad Sci USA 104 6 (2007) 1919-1924
46. Whittle H.C., Brown J., Marsh K., Greenwood B.M., Seidelin P., Tighe H., et al. T-cell control of Epstein-Barr virus-infected B cells is lost during P. falciparum malaria. Nature 312 5993 (1984) 449-450
47. D'Ombrain M.C., Voss T.S., Maier A.G., Pearce J.A., Hansen D.S., Cowman A.F., et al. Plasmodium falciparum erythrocyte membrane protein-1 specifically suppresses early production of host interferon-gamma. Cell Host Microbe 2 2 (2007) 130-138
48. Urban B.C., Ferguson D.J., Pain A., Willcox N., Plebanski M., Austyn J.M., et al. Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells. Nature 400 6739 (1999) 73-77
49. Moormann A.M., Chelimo K., Sumba P.O., Tisch D.J., Rochford R., and Kazura J.W. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis 195 6 (2007) 799-808
50. Wei W.I., and Sham J.S. Nasopharyngeal carcinoma. Lancet 365 9476 (2005) 2041-2054
51. Borza C.M., and Hutt-Fletcher L.M. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 8 6 (2002) 594-599
52. Heussinger N., Buttner M., Ott G., Brachtel E., Pilch B.Z., Kremmer E., et al. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 203 2 (2004) 696-699
53. Henle G., and Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17 1 (1976) 1-7
54. Lin X., Gudgeon N.H., Hui E.P., Jia H., Qun X., Taylor G.S., et al. CD4 and CD8 T cell responses to tumour-associated Epstein-Barr virus antigens in nasopharyngeal carcinoma patients. Cancer Immunol Immunother (2007)
55. Li J., Zeng X.H., Mo H.Y., Rolen U., Gao Y.F., Zhang X.S., et al. Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy. PLoS ONE 2 11 (2007) e1122
56. high regulatory T cells in nasopharyngeal carcinoma patients. Br J Cancer 96 4 (2007) 617-622
57. Lee S.P., Chan A.T., Cheung S.T., Thomas W.A., CroomCarter D., Dawson C.W., et al. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen- processing function of the tumor cells. J Immunol 165 1 (2000) 573-582
58. Khanna R., Busson P., Burrows S.R., Raffoux C., Moss D.J., Nicholls J.M., et al. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res 58 2 (1998) 310-314
59. Ogino T., Moriai S., Ishida Y., Ishii H., Katayama A., Miyokawa N., et al. Association of immunoescape mechanisms with Epstein-Barr virus infection in nasopharyngeal carcinoma. Int J Cancer 120 11 (2007) 2401-2410
60. Kutok J.L., and Wang F. Spectrum of Epstein-Barr virus-associated diseases. Annu Rev Pathol 1 (2006) 375-404
61. Babcock G.J., and Thorley-Lawson D.A. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci USA 97 22 (2000) 12250-12255
62. Herbst H., Foss H.D., Samol J., Araujo I., Klotzbach H., Krause H., et al. Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin's disease. Blood 87 7 (1996) 2918-2929
63. Kapp U., Yeh W.C., Patterson B., Elia A.J., Kagi D., Ho A., et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 189 12 (1999) 1939-1946
64. Hsu S.M., Lin J., Xie S.S., Hsu P.L., and Rich S. Abundant expression of transforming growth factor-beta 1 and -beta 2 by Hodgkin's Reed-Sternberg cells and by reactive T lymphocytes in Hodgkin's disease. Hum Pathol 24 3 (1993) 249-255
65. McKenzie G.J., Emson C.L., Bell S.E., Anderson S., Fallon P., Zurawski G., et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 9 3 (1998) 423-432
66. Gandhi M.K., Moll G., Smith C., Dua U., Lambley E., Ramuz O., et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 110 4 (2007) 1326-1329
67. Marshall N.A., Christie L.E., Munro L.R., Culligan D.J., Johnston P.W., Barker R.N., et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103 5 (2004) 1755-1762
68. + T-cell function in Hodgkin lymphoma patients. Blood 108 7 (2006) 2280-2289
69. Lee S.P., Constandinou C.M., Thomas W.A., Croom-Carter D., Blake N.W., Murray P.G., et al. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on Epstein-Barr virus-specific cytotoxic T-cell recognition. Blood 92 3 (1998) 1020-1030
70. Murray P.G., Constandinou C.M., Crocker J., Young L.S., and Ambinder R.F. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood 92 7 (1998) 2477-2483
71. Hjalgrim H., Askling J., Rostgaard K., Hamilton-Dutoit S., Frisch M., Zhang J.S., et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 349 14 (2003) 1324-1332
72. Sauce D., Larsen M., Curnow S.J., Leese A.M., Moss P.A., Hislop A.D., et al. EBV-associated mononucleosis leads to long-term global deficit in T cell responsiveness to IL-15. Blood 108 1 (2006) 11-18
73. Moutschen M., Leonard P., Sokal E.M., Smets F., Haumont M., Mazzu P., et al. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine 25 24 (2007) 4697-4705
74. + T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol 82 3 (2008) 1448-1457
75. Papadopoulos E.B., Ladanyi M., Emanuel D., Mackinnon S., Boulad F., Carabasi M.H., et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 330 17 (1994) 1185-1191
76. Gottschalk S., Rooney C.M., and Heslop H.E. Post-transplant lymphoproliferative disorders. Annu Rev Med 56 (2005) 29-44
77. Duraiswamy J., Bharadwaj M., Tellam J., Connolly G., Cooper L., Moss D., et al. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res 64 4 (2004) 1483-1489
78. Duraiswamy J., Sherritt M., Thomson S., Tellam J., Cooper L., Connolly G., et al. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 101 8 (2003) 3150-3156
79. + T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J Immunol 177 7 (2006) 4897-4906
80. + T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res 62 23 (2002) 6952-6958
81. + T-cell response. Nat Rev Immunol 4 8 (2004) 595-602
82. +-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virus-induced B-cell proliferation. J Virol 77 22 (2003) 12088-12104
83. Adhikary D., Behrends U., Moosmann A., Witter K., Bornkamm G.W., and Mautner J. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med (2006)
84. + T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol 79 8 (2005) 4896-4907
85. + T cell responses more efficiently than EBV transformed B cells. Hum Immunol 66 9 (2005) 938-949
86. Bickham K., Goodman K., Paludan C., Nikiforow S., Tsang M.L., Steinman R.M., et al. Dendritic cells initiate immune control of Epstein-Barr virus transformation of B lymphocytes in vitro. J Exp Med 198 11 (2003) 1653-1663
87. Pan Y., Zhang J., Zhou L., Zuo J., and Zeng Y. In vitro anti-tumor immune response induced by dendritic cells transfected with EBV-LMP2 recombinant adenovirus. Biochem Biophys Res Commun 347 3 (2006) 551-557
88. + T-helper 1 responses. J Virol 75 18 (2001) 8649-8659
89. +-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J Virol 78 2 (2004) 768-778
90. + T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest 107 1 (2001) 121-130
91. + T-cell responses provide both helper and cytotoxic functions during Epstein-Barr virus infection and transformation of fetal cord blood B cells. J Virol 81 9 (2007) 4766-4775
92. + T-cell subsets mediate immune recognition of Epstein Barr virus nuclear antigen 1 in healthy virus carriers. Blood 109 3 (2007) 1138-1146
93. Moormann AM, Heller KN, Chelimo K, Embuvy P, Plontz-Snyder R, Otieno J, O'Dour M, Minz C, Rochford R. Children with endemic Burkitt's lymphoma are deficient in Epstein-Barr nuclear antigen 1-specific IFN-γ secreting T cell response. Int J Cancer, in press.
94. 4+ T cell responses to the vivel nuclear antigen 1. Int J Cancer 123 12 (2008) 2824-2831
95. Gurer C., Strowig T., Brilot F., Pack M., Trumpfheller C., Arrey F., Park C.G., Steinman R.M., and Münz C. Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses. Blood 112 (2008) 1231-1239